SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scribe Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$19.39−0.69 (-3.44%)
Close on Oct 19, 2026
- Market cap
- $48.01M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Scribe Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
9 buys · 0 sales
Net bought $71.34M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aghazadeh Behzad | 3,088,888 | 16.37% | 13D (active) | Jul 24, 2026 |
| RA Capital Management, L.P. | 1,802,178 | 9.60% | 13G (passive) | Jul 27, 2026 |
| ELI LILLY & Co | 1,388,161 | 7.30% | 13D (active) | Jul 23, 2026 |
| Orbimed Advisors LLC | 1,348,825 | 7.20% | 13D (active) | Jul 27, 2026 |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SCTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 352,097 | 1.86% | $6.86M | 0.44% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 135,567 | 0.72% | $2.64M | 0.23% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Benjamin L. Oakes | President, CEO, Director | 506,602 | 2.68% | Jul 27, 2026 |
| David Parrot | Chief Financial Officer | 2,666 | 0.01% | Jul 27, 2026 |
| Svetlana Lucas | Chief Business Officer | 33,695 | 0.18% | Jul 27, 2026 |
| Carl L. Gordon | Director | 348,825 | 1.84% | Jul 29, 2026 |
| Advisors Llc Orbimed | Director | 348,825 | 1.84% | Jul 29, 2026 |
| Capital GP VIII LLC OrbiMed | Director | – | – | Jul 29, 2026 |
| Behzad Aghazadeh | Director, 10% owner | – | – | Jul 28, 2026 |
| Capital Advisors LLC Avoro | Director, 10% owner | – | – | Jul 28, 2026 |
| Ventures LLC Avoro | Director | 3,088,888 | 16.32% | Jul 28, 2026 |
| Joshua Bleharski | Director | – | – | Jul 27, 2026 |
| James Dean Watson | Director | – | – | Jul 27, 2026 |
| Benjamin A. Horowitz | 10% owner | – | – | Jul 29, 2026 |
| AH Equity Partners Bio III, L.L.C. | 10% owner | – | – | Jul 29, 2026 |
| Marc L. Andreessen | 10% owner | – | – | Jul 29, 2026 |
| Jennifer A. Doudna | 10% owner | 603,547 | 3.19% | Jul 29, 2026 |
| AH Bio Fund II, L.P. | 10% owner | – | – | Jul 29, 2026 |
| AH Equity Partners Bio II, L.L.C. | 10% owner | 2,749,392 | 14.52% | Jul 29, 2026 |
| AH Bio Fund III, L.P. | 10% owner | – | – | Jul 29, 2026 |
| Brett Staahl | 10% owner | 524,336 | 2.77% | Jul 28, 2026 |
| LILLY & Co ELI | 10% owner | 1,054,828 | 5.57% | Jul 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ventures LLC Avoro Director | Jul 28, 2026 | Buy | +7,905 | $18.25 | $144.27K | 3,088,888 |
| AH Equity Partners Bio II, L.L.C. 10% owner | Jul 27, 2026 | Conversion | +2,051,742 | – | – | 2,051,742 |
| AH Equity Partners Bio II, L.L.C. 10% owner | Jul 27, 2026 | Conversion | +697,650 | – | – | 697,650 |
| AH Equity Partners Bio II, L.L.C. 10% owner | Jul 27, 2026 | Buy | +333,333 | $15.00 | $5.00M | 2,385,075 |
| Carl L. Gordon Director | Jul 27, 2026 | Conversion | +348,825 | – | – | 348,825 |
| Carl L. Gordon Director | Jul 27, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,348,825 |
| Jennifer A. Doudna 10% owner | Jul 27, 2026 | Conversion | +12,511 | – | – | 603,547 |
| Advisors Llc Orbimed Director | Jul 27, 2026 | Conversion | +348,825 | – | – | 348,825 |
| Advisors Llc Orbimed Director | Jul 27, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,348,825 |
| Ventures LLC Avoro Director | Jul 24, 2026 | Buy | +2,333,333 | $15.00 | $35.00M | 3,030,983 |
| Ventures LLC Avoro Director | Jul 24, 2026 | Buy | +50,000 | $22.31 | $1.12M | 3,080,983 |
| David Parrot Chief Financial Officer | Jul 23, 2026 | Buy | +1,333 | $15.00 | $20.00K | 1,333 |
| David Parrot Chief Financial Officer | Jul 23, 2026 | Buy | +1,333 | $15.00 | $20.00K | 1,333 |
| Svetlana Lucas Chief Business Officer | Jul 23, 2026 | Buy | +3,000 | $15.00 | $45.00K | 3,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.